Skip to content

Study · Randomized controlled trial · n = 387 · 2026

15 results

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.

Ekinci EI, Maldonado SG, Unseld A, Martinez JA, Hennige AM, Schoelch C

Diabetes, obesity & metabolism22 Jun 2026Cited by 1 (Europe PMC)

PMID42331726 (opens in a new tab)PMCIDPMC13448873 (opens in a new tab)DOI10.1111/dom.70861 (opens in a new tab)PepBankPUB-42331726
Read at sourcePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and normoglycaemia, survodutide produced no significant change in HOMA-β versus placebo.

    In plain wordsIn adults with overweight or obesity and normal glucose, survodutide did not significantly change HOMA-β compared with placebo.

    Peptide
    Survodutide
    Outcome
    No significant changeHOMA-β in trial 1404-0036
    Study

    n = 387

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    In trial 1404-0036, there was no significant change in HOMA-β with survodutide versus placebo, likely owing to normoglycaemia in participants.
    1 context sentence
    Summary · context
    Trial 1404-0036 randomised 387 participants with overweight/obesity and normoglycaemia to receive survodutide or placebo for 46 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and normoglycaemia, survodutide decreased HOMA-IR versus placebo.

    In plain wordsIn adults with overweight or obesity and normal glucose, survodutide lowered a marker of insulin resistance more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseHOMA-IR in trial 1404-0036
    Study

    n = 387

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Survodutide was associated with significant decreases in HOMA-IR, glucagon, C-peptide, fasting insulin, and FPG versus placebo, and significant increases in HMW adiponectin.
    1 context sentence
    Summary · context
    Trial 1404-0036 randomised 387 participants with overweight/obesity and normoglycaemia to receive survodutide or placebo for 46 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and normoglycaemia, survodutide decreased glucagon versus placebo.

    In plain wordsIn adults with overweight or obesity and normal glucose, survodutide lowered glucagon more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseGlucagon in trial 1404-0036
    Study

    n = 387

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Survodutide was associated with significant decreases in HOMA-IR, glucagon, C-peptide, fasting insulin, and FPG versus placebo, and significant increases in HMW adiponectin.
    1 context sentence
    Summary · context
    Trial 1404-0036 randomised 387 participants with overweight/obesity and normoglycaemia to receive survodutide or placebo for 46 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and normoglycaemia, survodutide decreased C-peptide versus placebo.

    In plain wordsIn adults with overweight or obesity and normal glucose, survodutide lowered C-peptide more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseC-peptide in trial 1404-0036
    Study

    n = 387

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Survodutide was associated with significant decreases in HOMA-IR, glucagon, C-peptide, fasting insulin, and FPG versus placebo, and significant increases in HMW adiponectin.
    1 context sentence
    Summary · context
    Trial 1404-0036 randomised 387 participants with overweight/obesity and normoglycaemia to receive survodutide or placebo for 46 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and normoglycaemia, survodutide decreased fasting insulin versus placebo.

    In plain wordsIn adults with overweight or obesity and normal glucose, survodutide lowered fasting insulin more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseFasting insulin in trial 1404-0036
    Study

    n = 387

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Survodutide was associated with significant decreases in HOMA-IR, glucagon, C-peptide, fasting insulin, and FPG versus placebo, and significant increases in HMW adiponectin.
    1 context sentence
    Summary · context
    Trial 1404-0036 randomised 387 participants with overweight/obesity and normoglycaemia to receive survodutide or placebo for 46 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and normoglycaemia, survodutide decreased fasting plasma glucose versus placebo.

    In plain wordsIn adults with overweight or obesity and normal glucose, survodutide lowered fasting blood glucose more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseFasting plasma glucose in trial 1404-0036
    Study

    n = 387

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Survodutide was associated with significant decreases in HOMA-IR, glucagon, C-peptide, fasting insulin, and FPG versus placebo, and significant increases in HMW adiponectin.
    1 context sentence
    Summary · context
    Trial 1404-0036 randomised 387 participants with overweight/obesity and normoglycaemia to receive survodutide or placebo for 46 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and normoglycaemia, survodutide increased high-molecular-weight adiponectin versus placebo.

    In plain wordsIn adults with overweight or obesity and normal glucose, survodutide raised high-molecular-weight adiponectin more than placebo.

    Peptide
    Survodutide
    Outcome
    IncreaseHMW adiponectin in trial 1404-0036
    Study

    n = 387

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Survodutide was associated with significant decreases in HOMA-IR, glucagon, C-peptide, fasting insulin, and FPG versus placebo, and significant increases in HMW adiponectin.
    1 context sentence
    Summary · context
    Trial 1404-0036 randomised 387 participants with overweight/obesity and normoglycaemia to receive survodutide or placebo for 46 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, survodutide increased HOMA-β, a beta-cell function marker, versus placebo.

    In plain wordsIn adults with type 2 diabetes on metformin, survodutide increased a marker of beta-cell function more than placebo.

    Peptide
    Survodutide
    Outcome
    IncreaseHOMA-β in trial 1404-0002
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    In trial 1404-0002, survodutide was associated with significant and rapid increases in HOMA-β versus placebo, with significant decreases in HOMA-IR, glucagon, and fasting plasma glucose (FPG).
    1 context sentence
    Summary · context
    Trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, survodutide decreased HOMA-IR, an insulin resistance marker, versus placebo.

    In plain wordsIn adults with type 2 diabetes on metformin, survodutide lowered a marker of insulin resistance more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseHOMA-IR in trial 1404-0002
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    In trial 1404-0002, survodutide was associated with significant and rapid increases in HOMA-β versus placebo, with significant decreases in HOMA-IR, glucagon, and fasting plasma glucose (FPG).
    1 context sentence
    Summary · context
    Trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, survodutide decreased glucagon versus placebo.

    In plain wordsIn adults with type 2 diabetes on metformin, survodutide lowered glucagon more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseGlucagon in trial 1404-0002
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    In trial 1404-0002, survodutide was associated with significant and rapid increases in HOMA-β versus placebo, with significant decreases in HOMA-IR, glucagon, and fasting plasma glucose (FPG).
    1 context sentence
    Summary · context
    Trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, survodutide decreased fasting plasma glucose versus placebo.

    In plain wordsIn adults with type 2 diabetes on metformin, survodutide lowered fasting blood glucose more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseFasting plasma glucose in trial 1404-0002
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    In trial 1404-0002, survodutide was associated with significant and rapid increases in HOMA-β versus placebo, with significant decreases in HOMA-IR, glucagon, and fasting plasma glucose (FPG).
    1 context sentence
    Summary · context
    Trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, survodutide produced no significant change in high-molecular-weight adiponectin.

    In plain wordsIn adults with type 2 diabetes on metformin, survodutide did not significantly change high-molecular-weight adiponectin.

    Peptide
    Survodutide
    Outcome
    No significant changeHMW adiponectin in trial 1404-0002
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant changes occurred in high-molecular-weight (HMW) adiponectin, C-peptide, or fasting insulin levels.
    1 context sentence
    Summary · context
    Trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, survodutide produced no significant change in C-peptide.

    In plain wordsIn adults with type 2 diabetes on metformin, survodutide did not significantly change C-peptide.

    Peptide
    Survodutide
    Outcome
    No significant changeC-peptide in trial 1404-0002
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant changes occurred in high-molecular-weight (HMW) adiponectin, C-peptide, or fasting insulin levels.
    1 context sentence
    Summary · context
    Trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, survodutide produced no significant change in fasting insulin.

    In plain wordsIn adults with type 2 diabetes on metformin, survodutide did not significantly change fasting insulin.

    Peptide
    Survodutide
    Outcome
    No significant changeFasting insulin in trial 1404-0002
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant changes occurred in high-molecular-weight (HMW) adiponectin, C-peptide, or fasting insulin levels.
    1 context sentence
    Summary · context
    Trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
  15. 15HumanRandomized controlled trialMechanism

    In both trials, absolute change in bodyweight explained the largest proportion of the variability in fasting insulin and HOMA-IR changes, but not the other changes.

    In plain wordsIn both trials, weight change explained the largest share of the variation in fasting insulin and insulin resistance changes, but not the other changes.

    Peptide
    Survodutide
    Outcome
    Not applicableContribution of bodyweight change to changes in fasting insulin and HOMA-IR
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Combining all survodutide dose groups for each trial, absolute change in bodyweight from baseline explained the largest proportion of total variability in changes from baseline in fasting insulin and HOMA-IR. However, it did not explain other changes observed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04667377

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Boehringer Ingelheimn = 3878 Mar 2021 to 7 Oct 2022

Obesity

Trial pageClinicalTrials.govUpdated 2 Nov 2023
CompletedPhase 2Results postedNCT04153929

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Boehringer Ingelheimn = 41330 Apr 2020 to 4 Nov 2021

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 29 Nov 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.